top of page
In a Meeting

PROJECTS

Photoacoustic Imaging Investment & Technology Platform

FRONT2.jpg

SaniMed Science Group has been actively involved in the evaluation, development, and commercialization ecosystem surrounding optoacoustic and photoacoustic imaging technologies since 2021.

​

Our engagement began with the evaluation of direct investment and commercialization opportunities involving TomoWave-related businesses and technologies in the United States and China. Through this process, SaniMed gained first-hand experience in technology diligence, investment structuring, advanced medical imaging, and cross-border commercialization.

​

As the strategy evolved, SaniMed moved away from pursuing a complex direct equity structure and instead supported the development of an independent operating platform in Shanghai through BioTech (Shanghai) Technology Co., Ltd.

​

The Shanghai platform is being developed to support life science technology application, research collaboration, equipment integration, technical training, application development, and cross-border commercialization.

​

The platform has invested in specialized photoacoustic imaging infrastructure, including a PhotoSonus tunable laser system sourced from TomoWave Laboratories, Inc., and a Maestro-RD photoacoustic/ultrasound dual-modality imaging system sourced from TomoWave (Suzhou) Medical Imaging Co., Ltd.

​

Together, these capabilities provide a foundation for research collaboration, technology evaluation, application development, training, and future commercialization activities involving photoacoustic and ultrasound imaging technologies.

​

This initiative reflects SaniMed's broader investment philosophy: capital alone is often not enough in life sciences. Sustainable value creation may also require operating infrastructure, technical resources, strategic partnerships, and hands-on commercialization support.

​

Jim Wu also serves as Director of Business Development at TomoWave Laboratories, where he supports business development, strategic partnerships, research collaborations, international market development, and commercialization activities.

​

Entity Clarification

SaniMed Science Group, TomoWave Laboratories, Inc., TomoWave (Suzhou) Medical Imaging Co., Ltd., and BioTech (Shanghai) Technology Co., Ltd. are separate legal entities. References on this page describe investment evaluation, business development, equipment procurement, technology collaboration, and strategic activities as applicable and do not imply ownership or control unless expressly stated.

Torskal: Pioneering Green Nanomedicine for Cancer Therapy

Image by Louis Reed

Torskal is an innovative French biotech company pioneering non-ionizing plasmonic photothermal therapy (PTT) for oncology, leveraging a proprietary green nanotechnology platform. Headquartered in La Réunion, France, the company focuses on highly targeted, sustainable cancer treatments using plant-derived gold nanoparticles with superior biocompatibility and minimal environmental impact.

Torskal’s lead program, TSK-001, is designed for nodular basal-cell carcinoma (BCC), the most common form of skin cancer. The therapy employs near-infrared light to activate tumor-localized nanoparticles, generating precise, localized heat to eradicate malignant cells while sparing healthy tissue—offering a non-invasive, non-toxic alternative to radiation and chemotherapy.

Founded and led by Dr. Anne-Laure Morel, an expert in green nanochemistry, Torskal holds a robust patent portfolio granted in over 40 countries. The company is currently advancing toward Phase 1–2 clinical trials, aiming to translate sustainable photothermal therapy into clinical reality.

Services

International Investment and Financing Services:

  • Angel and Early-Stage investments

  • International incubation with equity holdings

  • Financing consulting

  • Investment matchmaking activities

  • Industrial Park connection services

International Market Access Consulting Services:

  • FDA Regulatory Strategy & U.S. Market Entry Support

  • International standard testing

  • FDA QMSR / ISO 13485 quality management system support

  • Medical device registration and clinical evaluation

Market Promotion and Sales:

  • Promotion and sales of biopharmaceutical and medical device products in North American and Asian markets

  • Establishment of a global online sales system

  • Operation of warehousing and logistics services in North America and Asia

Production Outsourcing and Global Procurement Services:

  • Process research and validation for products

  • Original equipment manufacturing for pilot and post-market stages of products.

  • Procurement and customized procurement services for medical devices and research experimental products.

bottom of page